Study for the effect of Stronger Neo-Minophagen C (SNMC) for nonalcoholic fatty liver disease (NAFLD)-multicenter clinical trial-

Study for the effect of Stronger Neo-Minophagen C (SNMC) for nonalcoholic fatty liver disease (NAFLD)-multicenter clinical trial- - Study for the effect of SNMC for NAFLD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012336

Enrollment

Registered

2013-11-25

Start date

2013-11-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease

Interventions

Stronger Neo-Minophagen C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Fatty liver is diagnosed by ultrasonography. 2. ALT is more than 30 IU/L or abnormal of gamma GTP. 3. Abailable to continue to recieve Stronger Neo-Minophagen C for 1 month. 4. Obtained written informed concent from patient.

Exclusion criteria

Exclusion criteria: 1. HBV or HCV infection. 2. Alcohol drinking more than 20g-ethanol per day. 3. Malignancy 4. Hepatic encephalopathy 5. Active infection 6. Severe complication 7. Pregnant, child-bearing potential or breast-feeding woman. 8. Ineligible for study judged by Medical Docor

Design outcomes

Primary

Measure	Time frame
ALT, gamma-GTP	—

Countries

Japan

Contacts

Public ContactHirofumi Uto

Kagoshima University Hospital Division of Gstroenterological Mdicine

hirouto@m2.kufm.kagoshima-u.ac.jp099-275-5326

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026